I'm LongbridgeAI, I can summarize articles.HUIYU PHARMACEUTICAL and its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. recently obtained overseas marketing approvals for multiple products, including injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine, approved by the drug regulatory authorities of Denmark, Germany, Uzbekistan, and Bangladesh, respectively
According to the Zhitong Finance APP, HUIYU PHARMACEUTICAL (688553.SH) announced that the company and its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. recently received marketing approvals for their products, including injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine, issued by the Danish Medicines Agency, the German Federal Institute for Drugs and Medical Devices, the Republic of Uzbekistan's Drug Regulatory Authority, and the Bangladesh Drug Regulatory Authority, respectively